1. Home
  2. /
  3. COA in the News

COA in the News


May 21

2019

Community Oncology Alliance Pushing Alternative to Pricing Index for Part B Drugs

The Community Oncology Alliance is in discussions with congressional staff and the Trump administration about modifying the existing Medicare Part B payment structure as an alternative to the International Pricing Index that HHS Secretary Alex Azar has proposed for Part B drugs.

Read more

May 20

2019

CMS Reverses Course: ‘Protected’ Drug Classes Still Covered

The federal government has backed off a proposal that would have let Medicare Part D prescription drug plans deny coverage for therapies in six "protected" classes of drugs, including those for cancer and psychiatric conditions.

Read more

May 20

2019

Busting the Myth of “Perverse Physician Incentives” to Prescribe High-Cost Drugs

As proposals directed at reducing the cost of prescription drugs are being discussed at the national level, the Community Oncology Alliance (COA) has taken a closer look at the assertion that oncologists who prescribe and administer drugs within the Medicare Part B system are incentivized to prescribe more expensive drugs for profit. As it

Read more

May 20

2019

Barry Russo: Alliances Between Practices Are Invaluable to the Future of Cancer Care

Alliances are going to help community oncology participate in things that, as individual practices, they don‘t have the opportunity to do, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.

Read more

May 17

2019

‘Immoral, Barbaric’ Denials; Huge Roundup Award; PBM ‘Abuse’

After calling UnitedHealthcare's refusal to cover proton therapy for cancer "immoral and barbaric," a federal judge -- and cancer survivor -- recused himself from a case involving one of those coverage denials.

Read more

May 9

2019

Cancer Patients Should be Treated by Their Doctors, not Pharmacy Benefit Managers

When I must tell a patient that she or he has cancer, that diagnosis comes with the explicit promise that I will provide timely treatment, including medicines aimed at curing cancer or extending life as long as possible. But an insidious interloper now often comes between me and my patients. I’m talking about pharmacy benefit

Read more

Apr 22

2019

Unlocking the Potential of Biosimilars in Community Oncology

Today, biologics make up more than half of the oncologic therapies in the pipeline. These pioneering therapies now allow more than 350 million patients with cancer globally to receive their treatment through a painless injection rather than an 8-hour chemotherapy session.1 

Read more

Apr 17

2019

Busting the Myth of “Perverse Physician Incentives” to Prescribe High-Cost Drugs

As proposals directed at reducing the cost of prescription drugs are being discussed at the national level, the Community Oncology Alliance (COA) has taken a closer look at the assertion that oncologists who prescribe and administer drugs within the Medicare Part B system are incentivized to prescribe more expensive drugs for profit. As it

Read more

Apr 17

2019

COA Releases Biosimilars Position Statement

The Community Oncology Alliance (COA) recently released a position statement about biosimilars, saying it will work with stakeholders to support the acceptance of biosimilars as well as work to close knowledge gaps, given the burdensome cost of cancer care.

Read more

Apr 12

2019

Senate Hearing puts Spotlight on Debate over Consolidation in PBM Market

As officials from the big three pharmacy benefit manager giants testified on Capitol Hill on Tuesday, it was their sheer size that seemed to stick out most for senators.

Read more